Sorrento Therapeutics Inc

Most Recent

  • sorrento therapeutics stock
    Healthcare

    Sorrento Therapeutics' Stock Price Continues to Climb

    By Ambrish Shah
  • is sorrento therapeutics a good bet
    Healthcare

    Is Sorrento Therapeutics a Good Bet for Investors?

    Sorrento Therapeutics stock has surged 280 percent year-to-date. Will the rally continue?

    By Ambrish Shah
  • uploads///Graph
    Company & Industry Overviews

    Analysts Give Favorable Opinions on Sorrento Therapeutics

    Wall Street analysts expect a potential upside of 295.22% for Sorrento Therapeutics (SRNE) based on the stock’s closing price on March 21.

    By Margaret Patrick
  • uploads///SRNE
    Company & Industry Overviews

    Why the Sudden Surge in Sorrento Therapeutics’ Revenue?

    In fiscal 2017, Sorrento Therapeutics (SRNE) generated total revenue of $151.8 million compared to $8.1 million in fiscal 2016.

    By Kenneth Smith
  • uploads///SRNE
    Company & Industry Overviews

    Exploring Sorrento Therapeutics’ Research Pipeline

    Sorrento Therapeutics (SRNE) aims to use its antibodies along with its proprietary targeted delivery modalities to generate therapies for cancer.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Analysts’ Ratings for Sorrento and Its Peers in March 2018

    Of the two analysts covering Sorrento Therapeutics in March 2018, one analyst has given it a “strong buy” recommendation.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.